Genistein and cAMP signaling in vascular endothelium
Project Number1R21AT002739-01A2
Contact PI/Project LeaderLIU, DONGMIN
Awardee OrganizationVIRGINIA POLYTECHNIC INST AND ST UNIV
Description
Abstract Text
DESCRIPTION (provided by applicant): The long-range goal of this research is to develop novel vasoactive agents that may be of benefit in lowering the high level of cardiovascular morbidity in the aging American population. Recent studies have shown that ingestion of soy protein associated with isoflavones may have a protective role in vasculature. Genistein, the major soy isoflavone, has various biologgical actions. However, it is not clear whether the beneficial effect of soy protein is due to genistein or other components. In addition, the cellular or molecular mechanisms underlying the vessel protective effect of soy products remain unclear. We recently found that genistein directly acts on vascular dothelial cells (EC), leading to cAMP accumulation, nitric oxide synthase (eNOS) activation and expression. Further, We demonstrated that genistein induced a rapid decrease in systemic blood pressure (BP) in rats. The objective of this application, is therefore to determine how genistein triggers the cAMP signaling pathway and thereby influencing the cAMP-related vascular function. The four following questions will be addressed: 1). How does genistein elevate cAMP, activate eNOS, and consequently stimulate nitric oxide in EC? 2) Does genistein decrease BP in animals through activation of the cAMP signaling? 3). Does elevated cAMP by genistein also alter eNOS gene expression ? 4). Does genistein protect endothelial barrier function via the cAMP signaling? We will employ cellular, molecular and biochemical analysis to determine whether genistein elevates cAMP via activation of Gs-mediated adenylate cyclase in EC. Genistein-regulated eNOS gene expression will be evaluated by ribonuclease protection assay and Real-Time PCR. The effect of genistein on endothelial barrier function, as determined by cytoskeletal reorganization and barrier permeability, will be assessed using immunocytochemistry, confocal microscope and macromolecular leakage methods. Pharmacological and molecular intervention approaches will be used to detemine the involvement of a specific pathway in mediation of genistein action. The results from these studies will establish the mechanisms of the genistein action in vasculature and thereby provide foundation for further studies to determine the effects of genistein on vascular health and diseases such as hypertension. The demonstration of the health benefits of soy isoflavones in vasculature is expected to have significant effect on public health since isoflavones are widely used as a dietary supplements.
National Center for Complementary and Integrative Health
CFDA Code
213
DUNS Number
003137015
UEI
QDE5UHE5XD16
Project Start Date
01-September-2007
Project End Date
30-April-2009
Budget Start Date
01-September-2007
Budget End Date
30-April-2008
Project Funding Information for 2007
Total Funding
$199,751
Direct Costs
$125,000
Indirect Costs
$74,751
Year
Funding IC
FY Total Cost by IC
2007
National Center for Complementary and Integrative Health
$199,751
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AT002739-01A2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AT002739-01A2
Patents
No Patents information available for 1R21AT002739-01A2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AT002739-01A2
Clinical Studies
No Clinical Studies information available for 1R21AT002739-01A2
News and More
Related News Releases
No news release information available for 1R21AT002739-01A2
History
No Historical information available for 1R21AT002739-01A2
Similar Projects
No Similar Projects information available for 1R21AT002739-01A2